title: HP-β-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia-reperfusion injury in rats.
abstract: It is well known that puerarin attenuates ischemia-reperfusion injury and promotes function recovery of ischemic region. However, due to its reverse physiochemical properties, puerarin does not easily cross the blood-brain barrier. The aim of the present study is to create puerarin nanoparticles which increase and prolong the puerarin concentration in the brain. Using emulsion solvent evaporation techniques, we designed puerarin-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles. Hydroxypropyl beta cyclodextrin (HP-β-CD) was used to increase the solubility of puerarin and gelatin to enhance viscosity of inner water phase, which improved puerarin entrapment. The drug release kinetics and nanoparticle degradation in phosphate buffered saline (PBS) were analyzed by electronic microscopy and high-performance liquid chromatography. Computerized tomography scans were used to detect the infarction volume and electroencephalogram (EEG) was recorded to estimate the recovery of brain function. The results showed that the combined HP-β-CD and gelatin significantly improved the entrapment efficiency. The infarction volume was significantly decreased on days 3 and 7 after the administration of puerarin nanoparticles compared with that of control and pure puerarin. EEG was also significantly improved. Puerarin nanoparticles are potentially applicable for the brain injury induced by ischemic-reperfusion.
authors.affiliation: Department of Neurosurgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
authors.forename: Hai-quan
authors.initials: HQ
authors.lastname: Tao
authors.forename: Qingfeng
authors.initials: Q
authors.lastname: Meng
authors.forename: Ming-hui
authors.initials: MH
authors.lastname: Li
authors.forename: Hui
authors.initials: H
authors.lastname: Yu
authors.forename: Mei-fang
authors.initials: MF
authors.lastname: Liu
authors.forename: Dan
authors.initials: D
authors.lastname: Du
authors.forename: Shou-li
authors.initials: SL
authors.lastname: Sun
authors.forename: Hai-cheng
authors.initials: HC
authors.lastname: Yang
authors.forename: Yan-ming
authors.initials: YM
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Ye
authors.forename: Li-zhuang
authors.initials: LZ
authors.lastname: Yang
authors.forename: Da-ling
authors.initials: DL
authors.lastname: Zhu
authors.forename: Chuan-lu
authors.initials: CL
authors.lastname: Jiang
authors.forename: Hai-sheng
authors.initials: HS
authors.lastname: Peng
mesh_terms: D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000818:Animals; D001682:Biological Availability; D001812:Blood-Brain Barrier / Q000378:metabolism; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology; D002851:Chromatography, High Pressure Liquid; D004337:Drug Carriers / Q000737:chemistry; D005780:Gelatin / Q000737:chemistry; D007529:Isoflavones / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D019344:Lactic Acid / Q000737:chemistry*; D008297:Male; D053758:Nanoparticles; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000188:drug therapy / Q000473:pathology; D012995:Solubility; D013997:Time Factors; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D014783:Viscosity; D047392:beta-Cyclodextrins / Q000737:chemistry*
chemical_list: D004337:Drug Carriers; D007529:Isoflavones; D014665:Vasodilator Agents; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D005780:Gelatin; C033607:puerarin